Pathologists and the third wave of medical genomics

References

• 1  Drews J. Genomic sciences and the medicine of tomorrow. Nat. Biotechnol.14(11),1516–1518 (1996).
  Medline CASGoogle Scholar
• 2  Hopkins AL, Groom CR. The druggable genome. Nat. Rev. Drug Dis.1(9),727–730 (2002).
  Medline CASGoogle Scholar
• 3  Bassett DE Jr, Boguski MS, Spencer F et al. Genome cross-referencing and XREFdb: implications for the identification and analysis of genes mutated in human disease. Nat. Genet.15(4),339–344 (1997).
  Medline CASGoogle Scholar
• 4  Hieter P, Boguski M. Functional genomics: it’s all how you read it. Science278(5338),601–602 (1997).
  Medline CASGoogle Scholar
• 5  Shapiro L, Lima CD. The argonne structural genomics workshop: lamaze class for the birth of a new science. Structure6(3),265–267 (1998).
  Medline CASGoogle Scholar
• 6  Burton PR, Clayton DG, Cardon LR, et al.; Wellcome Trust Case Control Consortium.Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature477(7145),661–678 (2007).
  Google Scholar
• 7  Davies K. The $1,000 genome: the revolution in DNA sequencing and the new era of personalized medicine. Free Press, NY, USA (2010).
  Google Scholar
• 8  Davies K. Keeping score of your sequence. Bio-IT World, 12 November (2008).
  Google Scholar
• 9  Haspel RL, Arnaout R, Briere L et al. A Curriculum in genomics and personalized medicine for pathology residents. Am. J. Clin. Path.133(Online Suppl.),1–3 (2010).
  Google Scholar
• 10  Bloss CS, Madlensky L, Schork NJ, Topol EJ. Genomic information as a behavioral health intervention: can it work? Per. Med.8(6),659–667 (2011).
  Google Scholar
• 11  Boguski MS, Arnaout R, Hill C. Customized care 2020: how medical sequencing and network biology will enable personalized medicine. F1000 Biol. Rep.1,73 (2009).
  MedlineGoogle Scholar
• 12  Christensen CM, Grossman JH, Hwang J. The innovator’s prescription: a disruptive solution for health care. McGraw-Hill, NY, USA (2009).
  Google Scholar
• 13  Mardis ER. A decade’s perspective on DNA sequencing technology. Nature470(7333),198–203 (2011).
  Medline CASGoogle Scholar
• 14  Kuehn BG. NIH shifts focus from sequencing genes to fostering clinical applications. JAMA307(2),132 (2012).
  Medline CASGoogle Scholar
• 15  Haspel RL, Arnaout R, Briere L et al. A call to action: training pathology residents in genomics and personalized medicine. Am. J. Clin. Pathol.133(6),832–834 (2010).
  MedlineGoogle Scholar
• 16  Tonellato PJ, Crawford JM, Boguski MS, Saffitz JE. A national agenda for the future of pathology in personalized medicine: report of the proceedings of a meeting at the banbury conference center on genome-era pathology, precision diagnostics, and preemptive care: a stakeholder summit. Am. J. Clin. Pathol.135(5),668–672 (2011).
  MedlineGoogle Scholar
• 17  Centers for Medicare & Medicaid Services; US Department of Health and Human Services. Medicare, Medicaid and CLIA programs; continuance of the approval of the College of American Pathologists as a CLIA accreditation organization. Federal Register66(177),47493–47497 (2001).
  Google Scholar
• 18  Rabinovitch A. The college of American pathologists laboratory accreditation program. Accreditation and quality assurance. J. Qual. Comparability Reliability Chem. Measurement7(11),473–476 (2002).
  Google Scholar
• 101  Wolcott J, Schwartz A, Goodman C; The Lewin Group. Laboratory medicine: a national status report (2008). www.futurelabmedicine.org/pdfs/2007%20status%20report%20laboratory_medicine_-_a_national_status_report_from_the_lewin_group_updated_2008-9.pdf
  Google Scholar